SEI Investments’s TherapeuticsMD TXMD Stock Holding History

SEI Investments’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-17	Closed	-$4K	–	3786
2018 Q1	$4K	Hold	17	–	–	﹤0.01%	3120
2017 Q4	$5K	Buy	+17	New	+$4.73K	﹤0.01%	2960
2015 Q4	–	Sell	-1,192	Closed	-$349K	–	2692
2015 Q3	$349K	Buy	+1,192	New	+$424K	﹤0.01%	1421

Other funds holding TXMD

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

SEI Investments's TXMD Position: Q2 2018 in Review

SEI Investments sold out of TherapeuticsMD (TXMD) in Q2 2018, closing a stake of 17 shares — an estimated $4K sold.

SEI Investments first reported a position in TXMD in Q3 2015 and held it in 3 quarters. The position peaked at $349K in Q3 2015. 144 funds tracked by Wall St. Rank hold TXMD as of Q2 2018.

SEI Investments reported no remaining TherapeuticsMD position as of Q2 2018 after selling out during the quarter.
SEI Investments sold 17 TherapeuticsMD shares in Q2 2018, an estimated $4K.
SEI Investments first reported a position in TherapeuticsMD in Q3 2015 and held it in 3 quarters.
SEI Investments's TherapeuticsMD position peaked at $349K in Q3 2015.
144 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2018.

Based on SEI Investments's 13F filing for Q2 2018, filed 3 Aug 2018.